Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema  in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025

Celldex Therapeutics (CLDX) announced positive Phase 2 clinical trial data for barzolvolimab in chronic spontaneous urticaria (CSU), demonstrating significant improvements in angioedema symptoms over 52 weeks; specifically, up to 77% of patients with angioedema at baseline were angioedema-free at Week 52. The data, presented at the EAACI Congress 2025, showed rapid and robust reductions in angioedema, supporting barzolvolimab's potential to redefine CSU treatment and improve patient quality of life. Celldex is currently conducting a global Phase 3 program for barzolvolimab in CSU.

Analysis

Celldex Therapeutics (NASDAQ:CLDX) has reported highly positive 52-week data from its Phase 2 clinical trial of barzolvolimab in chronic spontaneous urticaria (CSU), specifically demonstrating profound improvements in angioedema. Notably, 77% of patients receiving the 150 mg Q4W dose who presented with angioedema at baseline were angioedema-free at Week 52. The study also showed substantial mean reductions from baseline in the weekly angioedema activity score (AAS7) at Week 52, with an 86% reduction for the 150 mg Q4W arm and an 82% reduction for the 300 mg Q8W arm. These long-term results build upon previously announced positive 12-week primary and secondary endpoint data, where barzolvolimab achieved clinically meaningful and statistically significant decreases in UAS7 compared to placebo and showed a favorable safety profile. The company highlighted that patients treated with barzolvolimab were angioedema-free up to 72% of the time over the 52-week treatment period, and up to 87% reported clinically meaningful improvement in AAS7. These findings, coupled with previously presented 76-week efficacy and safety data, underscore barzolvolimab's potential to significantly alter the CSU treatment paradigm by offering rapid, profound, and durable responses, thereby improving quality of life for patients suffering from this debilitating condition, characterized by painful swelling. Celldex is now advancing barzolvolimab into a global Phase 3 program (EMBARQ-CSU1 and EMBARQ-CSU2), with enrollment currently underway, aiming to confirm these benefits in a larger patient population, including those who remain symptomatic despite H1 antihistamine treatment or biologics.

Key Decisions for Investors

• The compelling 52-week Phase 2 efficacy and safety data for barzolvolimab, particularly the high rates of angioedema resolution and sustained improvement, significantly de-risk its clinical development for chronic spontaneous urticaria, positioning it as a potentially leading therapy.
• Investors should closely monitor the progress and upcoming data readouts from Celldex's ongoing global Phase 3 trials (EMBARQ-CSU1 and EMBARQ-CSU2), as these will be critical catalysts for the company's valuation and barzolvolimab's path to market.
• Considering the drug's mechanism as a KIT inhibitor and its demonstrated ability to achieve rapid, profound, and durable responses in CSU, continued positive developments could substantially enhance Celldex's market position, though inherent clinical trial and regulatory risks outlined by the company warrant careful consideration.